List of Excipients in Branded Drug BAYER ALEVE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Acme United Corporation	BAYER ALEVE	naproxen sodium	0924-6000	CELLULOSE, MICROCRYSTALLINE
Acme United Corporation	BAYER ALEVE	naproxen sodium	0924-6000	FD&C BLUE NO. 2
Acme United Corporation	BAYER ALEVE	naproxen sodium	0924-6000	HYPROMELLOSES
Acme United Corporation	BAYER ALEVE	naproxen sodium	0924-6000	MAGNESIUM STEARATE
Acme United Corporation	BAYER ALEVE	naproxen sodium	0924-6000	POLYETHYLENE GLYCOL

Bayer Aleve Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Bayer Aleve is an over-the-counter naproxen sodium product whose commercial value comes from long duration, strong consumer recognition, and broad analgesic use rather than active-ingredient exclusivity. Its core 220 mg caplet is a mature immediate-release formulation with limited patent leverage. The strongest opportunities are differentiated dosage forms, faster or easier administration, improved swallowability, packaging, and compliant co-medication formats.

What is Bayer Aleve and which excipients support its formulation?

Bayer Aleve contains naproxen sodium, equivalent to 220 mg of naproxen per tablet or caplet. The product is positioned for temporary relief of minor aches and pains and reduction of fever. Naproxen sodium is the salt form selected for faster dissolution than naproxen free acid in an immediate-release product.

A representative U.S. Aleve caplet label identifies inactive ingredients that may include microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, talc, polyethylene glycol, titanium dioxide, and colorants, depending on the specific SKU and market [1].

Formulation function	Typical excipient role in Aleve-type caplets	Commercial purpose
Diluent	Microcrystalline cellulose	Tablet mass, compression, mechanical strength
Superdisintegrant	Croscarmellose sodium	Rapid tablet breakup and drug release
Binder	Povidone	Granule and tablet strength
Lubricant	Magnesium stearate	Ejection from tablet press
Glidant or anti-adherent	Talc	Powder flow and manufacturing performance
Film coating	Polyethylene glycol, titanium dioxide, pigments	Swallowability, appearance, protection
Colorant	Approved lake or pigment	Brand recognition and product differentiation

The excipient system is conventional. Its value lies in controlling manufacturability and release behavior at high-volume consumer-health scale. Aleve does not require a complex delivery platform for its primary indication.

What excipient strategy is optimal for Aleve immediate-release tablets?

The best base strategy is a robust, low-cost immediate-release platform that maintains rapid disintegration, consistent dissolution, and low tablet weight.

Direct compression versus wet granulation

Direct compression can reduce processing steps and improve manufacturing economics, but naproxen sodium presents challenges related to powder flow, compactibility, segregation, and lubrication sensitivity. A direct-compression formulation would typically require a balanced combination of:

• Microcrystalline cellulose or silicified microcrystalline cellulose for compactibility.
• Croscarmellose sodium or sodium starch glycolate for disintegration.
• Colloidal silicon dioxide for flow.
• Low-concentration magnesium stearate for lubrication.

Wet granulation may provide better content uniformity and tablet strength, particularly for high-volume production across multiple sites. It adds drying capacity, process controls, and potential moisture exposure. A commercial decision would depend on equipment, supply-chain resilience, and target cost per tablet.

Disintegration and dissolution

Naproxen sodium is more soluble than naproxen free acid, but the formulation still must control tablet breakup and dissolution under compendial conditions. Excessive binder or over-lubrication can slow release. Magnesium stearate concentration and blending time are critical because hydrophobic lubricant films can reduce wetting.

A competitive formulation should target:

• Rapid disintegration without tablet friability.
• Consistent dissolution across manufacturing sites.
• Low sensitivity to compression force.
• Stability under elevated temperature and humidity.
• No meaningful food-related delay in product performance.

A superdisintegrant blend may improve robustness across different tablet hardness targets. Crospovidone can be evaluated against croscarmellose sodium where faster wicking, lower swelling, or reduced sensitivity to formulation density is desirable.

Coating and swallowability

Aleve tablets are commonly film-coated. The coating should reduce chalkiness, mask taste, protect the tablet, and support brand recognition without materially delaying immediate release.

A thin aqueous film coating based on hypromellose or a comparable polymer could reduce volatile organic solvent use and improve manufacturing safety. Polyethylene glycol is used as a plasticizer in many coating systems. Titanium dioxide remains subject to market-specific regulatory and customer restrictions, making titanium-dioxide-free pigment systems commercially relevant in some jurisdictions.

What formulation patents protect Bayer Aleve?

The core Aleve formulation has limited current patent value because naproxen and naproxen sodium are long-established active ingredients. The foundational composition, salt, and conventional immediate-release tablet concepts are outside their original patent terms.

IP category	Likely current position for core Aleve	Commercial implication
Naproxen active ingredient	Expired	No active-ingredient exclusivity
Naproxen sodium salt	Expired or effectively non-blocking for ordinary OTC use	Generic and private-label competition
Conventional tablet excipients	Generally unpatentable as broad concepts or vulnerable to design-around	Low barrier
Specific manufacturing process	Potentially protectable if novel and non-obvious	Limited value unless it lowers cost or improves quality
Novel dosage form	Potentially patentable	Main route to new exclusivity
Combination product	Potentially patentable, subject to prior art and regulatory requirements	Possible commercial extension
Packaging or dispensing system	Potentially protectable	Useful for adherence and premium positioning

No broad patent estate should be assumed to block a third party from producing a conventional 220 mg naproxen sodium OTC tablet. The commercially relevant IP opportunity is a narrow patent covering a new delivery system, dosage form, excipient combination, manufacturing process, or package architecture.

What is the Orange Book status of Aleve?

Aleve is an OTC product and its regulatory position differs from that of a conventional prescription drug with active Orange Book patent listings. The core product is marketed under the FDA OTC internal analgesic framework and related labeling requirements, including 21 C.F.R. Part 343 [2].

A competitor generally does not need to defeat an Aleve patent to launch a compliant naproxen sodium product. It must satisfy the applicable OTC monograph or obtain an FDA-approved application when the product falls outside the monograph conditions.

When does Aleve lose exclusivity?

Aleve has already lost active-ingredient and conventional formulation exclusivity. Its current protection is primarily brand-based.

Exclusivity type	Status
Active pharmaceutical ingredient exclusivity	Expired
Original prescription-era exclusivity	Expired
OTC switch exclusivity	Expired
Conventional 220 mg tablet protection	Not a meaningful current barrier
Trademark and trade dress	Ongoing if maintained and enforceable
Proprietary formulation or packaging	Product-specific and potentially limited
FDA OTC monograph position	Available to compliant competitors

The competitive moat is therefore based on brand equity, retail placement, advertising, consumer trust, and product execution. Private-label naproxen sodium products can compete on price because they do not need to reproduce Bayer’s brand assets.

What generic entry risks exist for Bayer Aleve?

The generic entry risk is structurally high. Naproxen sodium 220 mg is available from multiple manufacturers in tablets, caplets, gelcaps, and store-brand products. A conventional competitor can use different excipients and tablet geometry while preserving the same active ingredient, strength, route, and indication.

Paragraph IV challenges

Paragraph IV litigation is less central for a monograph-eligible OTC product than for a prescription drug protected by listed Orange Book patents. A competitor typically pursues one of two routes:

1. Market a product that complies with the OTC monograph.
2. Submit an FDA application for a product outside the monograph or requiring approved labeling.

A Paragraph IV challenge would become commercially relevant only if Bayer relied on an approved NDA with listed patents covering a particular formulation, dosage form, or indication. Core Aleve brand competition does not depend on that pathway.

Generic launch scenarios

Scenario	Probability profile	Effect on Aleve
Low-price conventional tablet	High	Pricing pressure in mass retail and e-commerce
Private-label caplet	High	Share erosion among price-sensitive consumers
Naproxen sodium gelcap	Moderate	Competition on swallowability and onset perception
Combination analgesic	Moderate	Shelf-space and basket-size pressure
Premium fast-release product	Moderate	Threat to higher-margin branded SKUs
Pediatric or liquid product	Lower	Regulatory and palatability barriers create differentiation

What commercial opportunities exist for Aleve excipient innovation?

Fast-release naproxen sodium

A fast-release product could use particle-size engineering, wetting agents, porous excipients, or a rapidly disintegrating matrix. The commercial claim must remain consistent with FDA labeling and supported by comparative dissolution and clinical data where required.

Potential excipient tools include:

• Crospovidone for rapid capillary action.
• Sodium lauryl sulfate or another wetting agent at a justified low level.
• Mannitol or other water-soluble fillers in orally disintegrating formats.
• Spray-dried excipient systems for improved compactibility.
• Lipid or polymer dispersion approaches for improved wetting, although these add cost and process complexity.

The main opportunity is a credible, measurable reduction in time to pharmacodynamic effect. A formulation that only improves laboratory dissolution without a consumer-perceivable benefit may not support premium pricing.

Easy-swallow caplets and mini-tablets

Swallowability is a practical opportunity for older adults and consumers who have difficulty taking conventional caplets. Options include:

• Smaller units with multi-tablet dosing.
• Oblong caplets with optimized aspect ratio.
• Low-friction film coatings.
• Smooth gelcap shells.
• Tablet-in-tablet or multiparticulate formats.

A smaller tablet can improve administration but may increase unit count, packaging cost, and dosing errors. The preferred design is likely a low-friction caplet or softgel that preserves one-dose convenience.

Liquid gels

Liquid gels can improve swallowability and provide a premium alternative to compressed tablets. The formulation may use a solubilized or suspended naproxen sodium fill with suitable vehicles, suspending agents, antioxidants, and shell materials.

Commercial advantages include:

• Perceived ease of swallowing.
• Premium price potential.
• Distinct shelf presentation.
• Potentially faster dispersion than a conventional tablet.

Constraints include shell stability, leakage, oxygen and moisture control, manufacturing cost, and compatibility of the fill with gelatin or vegetarian capsule materials.

Chewable and orally disintegrating products

Chewable Aleve could expand access for consumers who do not prefer tablets. The central technical problem is taste. Naproxen sodium can require effective taste masking through:

• Polymer coating of drug particles.
• Ion-exchange resin complexes.
• Lipid barriers.
• Sweetener and flavor systems.
• Effervescent or rapidly dispersible matrices.

Taste masking may increase tablet size and delay release. A chewable product also requires careful control of dose uniformity, mouthfeel, dental acceptability, and label instructions.

Liquid and pediatric formats

A pediatric naproxen product could occupy a differentiated niche, but this is not a simple excipient extension of adult Aleve. It would require age-appropriate dosing, palatability work, preservative selection, microbial controls, dosing-device validation, and regulatory review.

Suspensions may use structured vehicles, wetting agents, suspending polymers, buffers, and sweeteners. The formulation must prevent sedimentation and allow reproducible redispersion. The market is smaller than adult OTC analgesics but has fewer direct naproxen sodium competitors.

Which excipient suppliers and manufacturers could support Aleve line extensions?

Potential supply-chain partners include global suppliers of pharmaceutical-grade cellulose, disintegrants, coating polymers, capsule shells, silica, and taste-masking technologies. The commercial screening criteria should include:

• Multi-region manufacturing capacity.
• DMF or equivalent regulatory support.
• Excipient change-control performance.
• Low nitrosamine and elemental-impurity risk.
• Supply continuity for high-volume products.
• Compatibility with Bayer quality systems.
• Ability to support pediatric, liquid, and softgel development.

For a mature OTC brand, dual sourcing is strategically important. A formulation that depends on one specialized excipient supplier can create more risk than value unless the excipient provides a clear performance advantage.

How does Aleve compare with Advil and Tylenol on excipient opportunities?

Brand	Active ingredient	Core differentiation	Excipient opportunity
Aleve	Naproxen sodium	Longer dosing interval	Fast release, swallowability, low-pill-count formats
Advil	Ibuprofen	Broad dose and dosage-form range	Liquids, softgels, rapid-release systems
Tylenol	Acetaminophen	Broad consumer familiarity and non-NSAID positioning	Pediatric liquids, chews, combination products
Generic naproxen sodium	Naproxen sodium	Price	Low-cost, acceptable conventional formats

Aleve’s long duration reduces the need for frequent dosing, so a premium product should improve onset, administration, or adherence rather than simply add more excipients. Advil has a stronger established presence in liquid gels and rapid-release formats, while Tylenol competes through formulation breadth and household penetration.

What FDA regulatory issues affect Aleve excipient innovation?

A conventional naproxen sodium product that complies with the applicable OTC monograph can avoid the full development burden of a novel prescription product. A formulation outside the monograph, a new active combination, a pediatric product, or a materially different dosage form may require an FDA application or additional regulatory support.

Key regulatory issues include:

• Conformance with the internal analgesic monograph.
• Permitted active ingredient, strength, dosage form, and labeling.
• Excipient safety and level of use.
• Dissolution and stability.
• Container-closure compatibility.
• Child-resistant packaging requirements.
• Labeling for NSAID risks and dosing limits.
• Manufacturing controls under current good manufacturing practice.

Excipient innovation cannot weaken the required warnings for gastrointestinal bleeding, cardiovascular risk, allergic reactions, or other NSAID-related risks. A new excipient system also must not create an apparent change in onset, duration, or dosing instructions that is unsupported by the approved regulatory framework.

What licensing and partnership opportunities exist?

Aleve’s most credible licensing opportunities are adjacent technologies rather than the core naproxen sodium molecule.

Potential targets include:

• Rapid-dissolution platforms.
• Taste-masking systems.
• Vegetarian softgel technology.
• Low-friction coating systems.
• Child-resistant dispensing systems.
• Unit-dose adherence packaging.
• Sustainable blister and bottle materials.
• Pediatric suspension platforms.
• Combination products with complementary OTC actives.

A partnership should be evaluated against three commercial tests: whether the technology produces a consumer-visible benefit, whether it can be manufactured at mass-market cost, and whether it creates defensible IP. A formulation patent with no retail differentiation has limited value. A modest patent position attached to a high-performing dosage form may have greater commercial utility.

What revenue exposure does Aleve face from formulation competition?

Bayer does not generally report Aleve revenue as a separate public line item. The brand is included within broader Bayer Consumer Health reporting, so precise product-level revenue exposure is not publicly available from standard annual reporting [3].

The main revenue risks are:

• Private-label substitution in tablets and caplets.
• Retailer pressure on shelf pricing.
• Migration to ibuprofen rapid-release products.
• Consumer preference for softgels and liquid gels.
• Reduced demand for traditional oral analgesics in selected markets.
• Product recalls or supply interruptions caused by packaging or excipient issues.

The strongest revenue-defense strategy is a portfolio architecture with a core value caplet, a premium easy-swallow or fast-release product, and targeted formats for travel, older consumers, and family use.

Key Takeaways

• Aleve is a mature OTC naproxen sodium brand with little remaining active-ingredient or conventional formulation exclusivity.
• The core excipient platform should prioritize immediate release, robust compression, dissolution consistency, stability, and low manufacturing cost.
• The most attractive commercial opportunities are fast-release formats, liquid gels, easy-swallow caplets, chewables, and selected pediatric products.
• Formulation patents are most defensible when they cover a measurable performance advantage, not a routine excipient substitution.
• Generic and private-label competition is structurally strong because competitors can rely on the OTC monograph pathway.
• Brand equity, retail execution, packaging, and dosage-form differentiation are more important than legacy patent protection.
• Aleve’s product-level revenue is not separately disclosed by Bayer, which limits precise revenue-at-risk calculations.
• Licensing value is concentrated in delivery, taste masking, packaging, and manufacturing technologies that can scale at OTC volumes.

FAQs

Can a generic manufacturer copy Aleve’s excipients?

No. A generic or private-label manufacturer can use a different excipient system if the product meets applicable FDA quality, labeling, dosage-form, and monograph requirements. Aleve’s brand and trade dress cannot be copied.

Is naproxen sodium more suitable than naproxen for rapid-release OTC products?

Yes. Naproxen sodium generally offers faster dissolution than naproxen free acid. The final onset profile still depends on particle properties, excipients, compression, coating, and gastrointestinal conditions.

Can a new Aleve formulation obtain patent protection?

Yes, but protection would need to arise from a novel and non-obvious formulation, dosage form, manufacturing process, combination, or package. A routine substitution of one standard disintegrant for another is unlikely to provide strong protection.

Are softgel Aleve products technically superior to caplets?

Not automatically. Softgels can improve swallowability and support premium positioning, but they add shell, fill, leakage, stability, and cost challenges. Performance must be demonstrated through dissolution, stability, and, where relevant, pharmacokinetic testing.

What is the most commercially attractive excipient innovation for Aleve?

A scalable fast-release or easy-swallow formulation is the strongest near-term opportunity. It addresses a consumer-visible problem while preserving Aleve’s established naproxen sodium positioning and once- or twice-daily dosing advantage.

References

1. DailyMed. (n.d.). Aleve naproxen sodium tablet, film coated: Drug facts and inactive ingredients. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-343

3. Bayer AG. (2024). Annual report 2023: Consumer Health. https://www.bayer.com/en/investors/annual-reports

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm